In this report we describe the establishment of a Neuro-Oncology Register (NOR) at the University Hospital of Maastricht, The Netherlands. The register includes data on numbers and types of primary central nervous system (CNS) tumours and neurological complications of systemic cancer. One of the objectives of the register is to determine the incidence rate of neuro-oncological complications in systemic tumours and the incidence and prevalence rates of primary CNS tumours in a well-defined population. The catchment area of the NOR was defined with the help of the Dutch Regional Cancer Register. It involves 140,819 inhabitants and will be considered as our catchment population. At present, 1,168 cases have been recorded since the NOR became operational. All neuro-oncological reports in 1988 were chosen for further analysis (n = 276). We diagnosed 79 metastatic complications from systemic cancer. Metastasis of the brain is the most frequent metastatic complication in our population, followed by epidural metastasis. As in other series, the lung and breast are the most frequently encountered tumour sites. The NOR is a clinically based register which, in co-operation with the Dutch Regional Cancer Register, will generate important epidemiological data on CNS complications.

Keywords:
Neuro-oncology, Register, Complications
This content is only available via PDF.
© 1992 S. Karger AG, Basel
1993
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.